Quantbot Technologies LP Sells 88,712 Shares of Haleon PLC Sponsored ADR $HLN

Quantbot Technologies LP lowered its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 64.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 49,067 shares of the company’s stock after selling 88,712 shares during the period. Quantbot Technologies LP’s holdings in Haleon were worth $440,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of HLN. Bank of America Corp DE lifted its holdings in Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after buying an additional 6,669,923 shares during the period. JPMorgan Chase & Co. raised its position in shares of Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock worth $107,503,000 after acquiring an additional 3,207,986 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Haleon by 3,031.5% in the 2nd quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after acquiring an additional 5,212,711 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of Haleon in the 3rd quarter valued at about $45,593,000. Finally, Raymond James Financial Inc. lifted its stake in shares of Haleon by 0.7% in the 2nd quarter. Raymond James Financial Inc. now owns 4,315,180 shares of the company’s stock valued at $44,748,000 after purchasing an additional 29,287 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on HLN shares. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Deutsche Bank Aktiengesellschaft lowered shares of Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Finally, HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.27 on Tuesday. Haleon PLC Sponsored ADR has a twelve month low of $8.71 and a twelve month high of $11.42. The stock’s 50 day moving average is $10.50 and its 200-day moving average is $9.85. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $45.71 billion, a price-to-earnings ratio of 26.32 and a beta of 0.18.

Haleon Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a dividend of $0.1307 per share. The ex-dividend date is Friday, April 10th. This represents a yield of 251.0%. Haleon’s dividend payout ratio is presently 28.21%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.